The FDA grants priority review status for Johnson & Johnson's (JNJ) bedaquiline drug, which...

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

The FDA grants priority review status for Johnson & Johnson's (JNJ) bedaquiline drug, which is a treatment for strains of tuberculosis that are resistant to other multiple drugs. The FDA is expected to decide on bedaquiline in early 2013 after J&J filed for approval in June.